Reducing Cancer Care Costs by Comparative and Cost-Effectiveness Research (CER)

Well, it’s the day after Labor Day, time to resume our discussion of Bending the Cost Curve in Cancer Care. We’ve reached the end of the list, on ideas to reduce oncology costs put forth by Drs. Smith and Hillner in the May 25 issue of the NEJM. Really this 10th and final point intended for […]

Posted in cancer treatment, clinical trials, Economics, health care costs, Oncology (cancer)Tagged , , , , , , , 2 Comments on Reducing Cancer Care Costs by Comparative and Cost-Effectiveness Research (CER)

Reducing Costs by Better Integration of Palliative Care in Cancer Treatment

We’re up to point 9 on the list – and nearing the end – on Bending the Cost Curve in Cancer Care from the May 26 NEJM. The suggestion from Drs. Smith and Hillner is that doctors better integrate palliative care into usual oncology care. The authors start this important section well: We can reduce […]

Posted in cancer treatment, health care costs, health care delivery, Oncology (cancer), Palliative CareTagged , , , , , , Leave a Comment on Reducing Costs by Better Integration of Palliative Care in Cancer Treatment

Reducing Cancer Care Costs: The Value of Physicians’ Cognitive Work

We’ve reached what may be my favorite of the proposed ways to reduce cancer care costs, published in the NEJM by Drs. Smith and Hillner. Idea Number 8 is to realign compensation to value cognitive services, rather than chemotherapy, more highly. What the authors are saying is that we’d save money if oncologists were paid more for […]

Posted in cancer treatment, Essential Lessons, health care costs, Life as a Doctor, Oncology (cancer), PolicyTagged , , , , , , , , 1 Comment on Reducing Cancer Care Costs: The Value of Physicians’ Cognitive Work

Breast Cancer Avastin Update

This afternoon Ed Silverman of Pharmalot reports that Roche has proposed a compromise to the FDA over Avastin’s use in women with metastatic breast cancer. The drug would be approved for use only in combination with paclitaxel (Taxol), for which the data are strongest, and with special warnings. He writes: The deal includes revised labeling […]

Posted in Breast Cancer, cancer treatment, Medical News, Oncology (cancer), PolicyTagged , , , , , Leave a Comment on Breast Cancer Avastin Update

Implications of the Oncology Drug Shortage

Today’s New York Times features an op-ed by Dr. Ezekiel Emanuel, on the oncology drug shortage. It’s a serious problem that’s had too-little attention in the press: Of the 34 generic cancer drugs on the market, as of this month, 14 were in short supply. They include drugs that are the mainstay of treatment regimens […]

Posted in cancer treatment, health care costs, health care delivery, Medical News, Oncology (cancer)Tagged , , , , Leave a Comment on Implications of the Oncology Drug Shortage

On Reducing Cancer Care Costs by Resetting Expectations, and Hope

Today we should move forward on the list published in the NEJM on Bending the Cost Curve in Cancer Care. We’re up to point 7 in our discussion, what’s 2nd in the authors’ proposed changes in attitudes and practice: “Both doctors and patients need to have more realistic expectations.” This point follows closely from the […]

Posted in Books, cancer treatment, health care costs, Medical Ethics, Oncology (cancer)Tagged , , , , , , , , , , 4 Comments on On Reducing Cancer Care Costs by Resetting Expectations, and Hope

NIH to Drop Requirement for Websites Disclosing Researchers’ Ties to Industry

Today’s word comes from Nature News that the NIH is dropping a proposed requirement for universities to disclose researchers’ financial ties to industry on websites. This is a loss for patients, who may not be aware of their doctors’ relationships with pharmaceutical companies and others who fund clinical trials, fellowships, conference junkets and other perks […]

Posted in Academic Medicine, clinical trials, Communication, Informed Consent, PolicyTagged , , , , , , , , , 1 Comment on NIH to Drop Requirement for Websites Disclosing Researchers’ Ties to Industry

Reducing Cancer Care Costs: Oncologists Need to Get a Grip on Reality, and Talk about Dying

We’ve reached the second half of our discussion on Bending the Cost Curve in Cancer Care. The authors of the NEJM paper, Drs. T. Smith and B. Hillner, go on to consider how doctors’ behavior influences costs in Changing Attitudes and Practice. Today’s point on the list: “Oncologists need to recognize that the costs of care are […]

Posted in cancer treatment, health care costs, Life as a Doctor, Oncology (cancer)Tagged , , , , , , 2 Comments on Reducing Cancer Care Costs: Oncologists Need to Get a Grip on Reality, and Talk about Dying

Lowering Cancer Care Costs by Limiting Chemotherapy in Patients Who Aren’t Responding

This is the sixth post on Bending the Cost Curve in Cancer Care, based on the 10 suggestions put forth by Drs. Smith and Hillner in the May 26 NEJM.  We’re up to number 5 on the list for changing oncologists’ behavior: by limiting further chemotherapy to clinical trial drugs in patients who are not […]

Posted in cancer treatment, clinical trials, health care costs, Oncology (cancer), Palliative CareTagged , , , , , , 2 Comments on Lowering Cancer Care Costs by Limiting Chemotherapy in Patients Who Aren’t Responding

The Big C: Cathy Goes For Treatment

In this week’s episode, Boo!, Cathy wakes up in the morning eager and ready to start treatment on a clinical trial. The day doesn’t go well – the local treatment center doesn’t have needed information about her insurance, which can’t be tracked down on time, her 15 year old son gets in trouble at school, […]

Posted in cancer treatment, clinical trials, Communication, Oncology (cancer), TVTagged , , Leave a Comment on The Big C: Cathy Goes For Treatment

Reducing Cancer Care Costs: Why Not Offer Neulasta in Smaller Vials?

This is the fifth in a series of posts on how we might reduce the costs of cancer care, based on 10 suggestions offered in a May, 2011 NEJM sounding board. We’re up to point 4:  oncologists should replace the routine use of white-cell-stimulating factors with a reduction in the chemotherapy dose in metastatic solid cancers. In […]

Posted in cancer treatment, health care costs, Oncology (cancer)Tagged , , , , , , , , , 6 Comments on Reducing Cancer Care Costs: Why Not Offer Neulasta in Smaller Vials?

Reducing Costs by Holding Back on Chemotherapy for Cancer Patients Who are Frail

This is the fourth in a series of posts on Bending the Cost Curve in Cancer Care, by Drs. Thomas J. Smith and Bruce E. Hillner, in a recent NEJM health policy piece. The authors’ third suggestion: to limit chemotherapy to patients with good performance status, with an exception for highly responsive disease, is surely one of the most […]

Posted in cancer treatment, Economics, health care costs, Medical Ethics, Oncology (cancer), PolicyTagged , , , , , , , , 5 Comments on Reducing Costs by Holding Back on Chemotherapy for Cancer Patients Who are Frail

Reducing Cancer Costs by Giving One Drug at a Time, Sequentially

This is the third in a series of posts on Bending the Cost Curve in Cancer Care, based on the late-May NEJM health policy piece. Today we’ll consider the second of the authors’ suggestions: to limit second and third-line treatments to sequential monotherapies for most solid tumors. This particular suggestion, one of the few proposed with which I […]

Posted in cancer treatment, health care costs, Oncology (cancer)Tagged , , Leave a Comment on Reducing Cancer Costs by Giving One Drug at a Time, Sequentially

Patients’ Words, Unfiltered, Medical Journalism and Evidence

Yesterday’s post was not really about Avastin, but about medical journalism and how patients’ voices are handled by the media. L. Husten, writing on a Forbes blog, cried that the press fawned, inappropriately, over patients’ words at the FDA hearing last week, and that led him to wonder why and if journalists should pay attention to […]

Posted in Breast Cancer, cancer treatment, Empowered Patient, health care costs, Medical News, Oncology (cancer), PolicyTagged , , , , , , , , 2 Comments on Patients’ Words, Unfiltered, Medical Journalism and Evidence

No Room For Emotion or Exceptions to the Rule (on Avastin)

My cousin testified before the FDA oncology advisory board on Tuesday about her experience taking Avastin. This is a tragedy, to deny the only drug that is keeping a 51 year old woman alive. You have to wonder, are the advisory panel members so rational in all their behavior and choices? Are they always so […]

Posted in Breast Cancer, cancer survival, cancer treatment, clinical trials, from the author, health care costs, Medical News, Oncology (cancer), PolicyTagged , , , , , , , , , 12 Comments on No Room For Emotion or Exceptions to the Rule (on Avastin)

Lowering Cancer Care Costs by Reducing Tests After Treatment

This is the second in a series of posts on Bending the Cost Curve in Cancer Care. We should consider the proposal, published in the NEJM, gradually over the course of this summer, starting with “suggested changes in oncologists’ behavior,” #1: 1. Target surveillance testing or imaging to situations in which a benefit has been […]

Posted in cancer survival, Empowered Patient, health care costs, Informed Consent, Oncology (cancer), Patient AutonomyTagged , , , , , , , 2 Comments on Lowering Cancer Care Costs by Reducing Tests After Treatment

Don Berwick, Head of CMS, on the Value of Patient-Centered Care

A few weeks ago I had the opportunity to hear Dr. Don Berwick speak at the annual meeting of the Association of Health Care Journalists. Berwick now heads the Centers for Medicare & Medicaid Services. When he spoke in April, on transparency and how we might simultaneously cut costs and improve care, I thought his […]

Posted in Communication, health care delivery, language, Medical Ethics, Patient Autonomy, Patient-Doctor RelationshipTagged , , , , , , 3 Comments on Don Berwick, Head of CMS, on the Value of Patient-Centered Care

Running 2 Lists That Might Lessen the Costs of Oncology Care

Recently the NEJM ran a Sounding Board piece on Bending the Cost Curve in Cancer Care. The authors take on this problem: Annual direct costs for cancer care are projected to rise — from $104 billion in 20061 to over $173 billion in 2020 and beyond.2…Medical oncologists directly or indirectly control or influence the majority […]

Posted in Future of Medicine, health care costs, Oncology (cancer), PolicyTagged , , , , , , , 2 Comments on Running 2 Lists That Might Lessen the Costs of Oncology Care

Give Doctors a Break

In a heartless op-ed in yesterday’s paper, an anesthesiologist argues that medicine shouldn’t be a part-time endeavor. Dr. Sibert makes a firm introduction: “I’m a doctor and a mother of four, and I’ve always practiced medicine full time,” she boasts. “When I took my board exams in 1987, female doctors were still uncommon, and we […]

Posted in Life as a Doctor, Life as a Patient, PolicyTagged , , , , , 7 Comments on Give Doctors a Break

Considering Aromasin for Healthy Women, and the New Breast Cancer Prevention Study

I’m minding the annual meeting of the American Society of Clinical Oncology from a distance this year. So far, the big breast cancer story syncs with a NEJM paper published yesterday on-line, on the use of exemestane (brand name: Aromasin, manufactured by Pfizer) to prevent invasive breast cancer. These patent-protected pills block the body’s normal […]

Posted in Breast Cancer, clinical trials, Medical News, Oncology (cancer), Women's HealthTagged , , , , , , , Leave a Comment on Considering Aromasin for Healthy Women, and the New Breast Cancer Prevention Study
newsletter software